What is the clinical evidence from this study?

Study design: Observational. Population: Adrenocortical carcinoma (n=29). Intervention: Next-generation sequencing. Primary outcome: Presence of at least one genomic alteration.

July 30, 2014Journal of Clinical Pathology63 citationsOpen Access

Next-generation sequencing of adrenocortical carcinoma reveals new routes to targeted therapies

JRJeffrey S. Ross KWK Wang JRJanne V. Rand

Key Result

Next-generation sequencing of 29 adrenocortical carcinoma samples identified at least one genomic alteration in 76% of cases, with 59% having targets for available therapies or clinical trials.

Study Design

Type

Observational (n=29)

Structured PICO

Does next-generation sequencing identify potential therapeutic targets in adrenocortical carcinoma?

Population

29 consecutive adrenocortical carcinoma samples undergoing comprehensive genomic profiling.

Exposure

Comprehensive genomic profiling / Next-generation sequencing (Illumina HiSeq)

Outcome

Genomic alterations (GAs) and potential targets of therapy

Next-generation sequencing of adrenocortical carcinoma identifies actionable genomic alterations in over half of cases, suggesting new targeted therapy options.

Abstract

AIMS: Adrenocortical carcinoma (ACC) carries a poor prognosis and current systemic cytotoxic therapies result in only modest improvement in overall survival. In this retrospective study, we performed a comprehensive genomic profiling of 29 consecutive ACC samples to identify potential targets of therapy not currently searched for in routine clinical practice. METHODS: DNA from 29 ACC was sequenced to high, uniform coverage (Illumina HiSeq) and analysed for genomic alterations (GAs). RESULTS: At least one GA was found in 22 (76%) ACC (mean 2.6 alterations per ACC). The most frequent GAs were in TP53 (34%), NF1 (14%), CDKN2A (14%), MEN1 (14%), CTNNB1 (10%) and ATM (10%). APC, CCND2, CDK4, DAXX, DNMT3A, KDM5C, LRP1B, MSH2 and RB1 were each altered in two cases (7%) and EGFR, ERBB4, KRAS, MDM2, NRAS, PDGFRB, PIK3CA, PTEN and PTCH1 were each altered in a single case (3%). In 17 (59%) of ACC, at least one GA was associated with an available therapeutic or a mechanism-based clinical trial. CONCLUSIONS: Next-generation sequencing can discover targets of therapy for relapsed and metastatic ACC and shows promise to improve outcomes for this aggressive form of cancer.

Ask AI

Helpful

Bookmark

View Full Paper